Detection of CYP2C19 alleles *I, *2 and *3 by multiplex polymerase chain reaction

Pharmacogenetics

Volumn 9, Issue 3, 1999, Pages 389-391

  Griese, E U ^a   Lapple F ^a   Eichelbaum, M ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

CYP2C19; Genotyping; Multiplex PCR

Indexed keywords

CELL DNA; CYTOCHROME P450 ISOENZYME; DIAZEPAM; IMIPRAMINE; OMEPRAZOLE; PROGUANIL; TAQ POLYMERASE;

ALLELE; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; EXON; GENE AMPLIFICATION; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HUMAN; INTRON; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; BASE SEQUENCE; CYTOCHROME P-450 ENZYME SYSTEM; DNA PRIMERS; HUMANS; MIXED FUNCTION OXYGENASES; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 0032767934     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Bertilsson L, Lou YQ, Du YL, Kuang X-Y, Liao, X-M, Wang K-Y, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin. Clin Pharmacol Ther 1992; 51:388-397.
2. Chang M, Dahl M-L, Tybring G, Götharson E, Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995; 5:358-363.
3. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamurai K, Meyer UA, Goldstein J. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994a; 22:15419-15422.
4. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin in Japanese. Mol Pharmacol 1994b; 46:594-598.
5. Edeki TI, Goldstein JA, de Morais SMF, Hajiloo L, Butler M, Chapdelaine P, Wilkinson GR. Genetic polymorphism of S-mephenytoin 4'-hydroxylation in African-Americans. Pharmacogenetics 1996; 6:357-360.
6. Ferguson RJ, de Morais SMF, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, et al. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for the poor metabolism of S-mephenytoin. JPET 1998; 284:356-361.
7. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994; 4:285-299.
8. Goldstein JA, Blaisdell J. Genetic tests which identify the principle defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Meth Enzymol 1996; 272:210-218.
9. Ibeanu GC, Blaisdell J, Ghanayem BI, Beyeler C, Benhamour S, Bouchardy C, et al. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics 1998a; 8:129-135.
10. Ibeanu GC, Goldstein JA, Meyer U, Benhamou S, Bouchardy C, Dayer PD, et al. Identification of new CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. JPET 1998b; 286:1490-1495.
11. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997; 37:269-296.
12. Stüven T, Griese E-U, Kroemer HK, Eichelbaum M, Zanger UM. Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction. Pharmacogenetics 1996; 6:417-421.
13. Roh HK, Dahl ML, Tybring G, Yamada H, Cha YN, Bertilsson L. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 1996; 6:547-551.
14. Xiao ZH, Goldstein JA, Xie H-G, Blaisdell J, Wang W, Jiang C-H, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Ban populations and identification of a new rare CYP2C19 mutant allele. JPET 1997; 281:604-609.